Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use

被引:204
|
作者
Baggish, Aaron L. [1 ,2 ]
Weiner, Rory B. [1 ,2 ]
Kanayama, Gen [3 ,4 ,5 ]
Hudson, James I. [3 ,4 ,5 ]
Lu, Michael T. [6 ,7 ]
Hoffmann, Udo [6 ,7 ]
Pope, Harrison G., Jr. [3 ,4 ,5 ]
机构
[1] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Performance Program, Boston, MA 02114 USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
[3] McLean Hosp, Biol Psychiat Lab, 115 Mill St, Belmont, MA 02178 USA
[4] McLean Hosp, Psychiat Epidemiol Res Program, 115 Mill St, Belmont, MA 02178 USA
[5] Harvard Med Sch, Dept Psychiat, Boston, MA USA
[6] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA
[7] Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA
关键词
anabolic-androgenic steroids; atherosclerosis; cardiology; cardiomyopathy; diastolic dysfunction; men; RISK-FACTORS; VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION; TISSUE DOPPLER; SOCIETY; WEIGHTLIFTERS; TESTOSTERONE; CONSEQUENCES; DYSFUNCTION; PREVALENCE;
D O I
10.1161/CIRCULATIONAHA.116.026945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remain incompletely understood. METHODS: Using a cross-sectional cohort design, we recruited 140 experienced male weightlifters 34 to 54 years of age, comprising 86 men reporting >= 2 years of cumulative lifetime AAS use and 54 nonusing men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction), LV diastolic function (early relaxation velocity), and coronary atherosclerosis (coronary artery plaque volume). RESULTS: Compared with nonusers, AAS users demonstrated relatively reduced LV systolic function (mean +/- SD left ventricular ejection fraction = 52 +/- 11% versus 63 +/- 8%; P < 0.001) and diastolic function (early relaxation velocity = 9.3 +/- 2.4 cm/second versus 11.1 +/- 2.0 cm/second; P < 0.001). Users currently taking AAS at the time of evaluation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49 +/- 10% versus 58 +/- 10%; P < 0.001) and diastolic function (early relaxation velocity = 8.9 +/- 2.4 cm/second versus 10.1 +/- 2.4 cm/second; P=0.035) compared with users currently off-drug (N=28). In addition, AAS users demonstrated higher coronary artery plaque volume than nonusers (median [interquartile range] 3 [0, 174] mL(3) versus 0 [0, 69] mL(3);P=0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10-year increase in cumulative duration of AAS use: 0.60 SD units [0.16-1.03 SD units]; P=0.008). CONCLUSIONS: Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS-associated adverse cardiovascular phenotypes may represent a previously underrecognized public-health problem.
引用
收藏
页码:1991 / +
页数:26
相关论文
共 50 条
  • [1] Illicit anabolic-androgenic steroid use
    Kanayama, Gen
    Hudson, James I.
    Pope, Harrison G., Jr.
    HORMONES AND BEHAVIOR, 2010, 58 (01) : 111 - 121
  • [2] EPIDEMIOLOGY AND PATTERNS OF ANABOLIC-ANDROGENIC STEROID USE
    YESALIS, CE
    PSYCHIATRIC ANNALS, 1992, 22 (01) : 7 - +
  • [3] Anabolic-androgenic steroid abuse
    Koziris, L
    PHYSICIAN AND SPORTSMEDICINE, 2000, 28 (12): : 67 - 68
  • [4] ANABOLIC-ANDROGENIC STEROID DEPENDENCE
    BROWER, KJ
    BLOW, FC
    BERESFORD, TP
    FUELLING, C
    JOURNAL OF CLINICAL PSYCHIATRY, 1989, 50 (01) : 31 - 33
  • [5] Trends in anabolic-androgenic steroid use among adolescents
    Yesalis, CE
    Barsukiewicz, CK
    Kopstein, AN
    Bahrke, MS
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1997, 151 (12): : 1197 - 1206
  • [6] Cutaneous manifestations of anabolic-androgenic steroid use in athletes
    Walker, Jennifer
    Adams, Brian
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2009, 48 (10) : 1044 - 1048
  • [7] Delayed rhabdomyolysis secondary to anabolic-androgenic steroid use
    Benjamin, Amelia
    Anderson, Alex
    Zrelec, Sanja
    CLINICAL MEDICINE, 2020, 20 (06) : E260 - E261
  • [8] Anabolic-Androgenic Steroid Use in Sports, Health, and Society
    Bhasin, Shalender
    Hatfield, Disa L.
    Hoffman, Jay R.
    Kraemer, William J.
    Labotz, Michele
    Phillips, Stuart M.
    Ratamess, Nicholas A.
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2021, 53 (08) : 1778 - 1794
  • [9] ANABOLIC-ANDROGENIC STEROID USE IN THE UNITED-STATES
    YESALIS, CE
    KENNEDY, NJ
    KOPSTEIN, AN
    BAHRKE, MS
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (10): : 1217 - 1221
  • [10] Anabolic-androgenic steroid use among 133 prisoners
    Pope, HG
    Kouri, EM
    Powell, KF
    Campbell, C
    Katz, DL
    COMPREHENSIVE PSYCHIATRY, 1996, 37 (05) : 322 - 327